Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down double digits in premarket trading.
Here's what could happen to Palantir's shares next.
Comedian Jerry Seinfeld is having the last laugh. New York is back in business. During the pandemic, when The New York Times published an article questioning if New York was over, Seinfeld hit back at the hand-wringing skeptics with a Times article of his own, “So You Think New York Is ‘Dead’ (It’s not).” He was right. Recent numbers show that the Big Apple’s commercial real estate numbers are back to pre-pandemic levels as workers return to the office en masse, breathing life into surrounding b
The new fund follows the launch of BlackRock's S&P 500 top-20 ETF.
Shares of Trump Media & Technology Group (DJT) slipped almost 4% in pre-market trading Friday, after regulatory filings showed President-elect Donald Trump moved the entirety of his stake in the company to a revocable trust.
The Federal Reserve’s key inflation measure came in below expectations for November, delivering welcome relief Friday to markets after the central bank warned earlier this week of mounting price pressures heading into the new year. The Personal Consumption Expenditures price index grew by 2.4% in November 2024 on a year-over-year basis, up from 2.3% in October, according to government data. The figure missed economist forecasts of 2.5%, yet it marked the second consecutive monthly increase in th
Former TD Ameritrade CEO Joe Moglia stops by to share why investors have plenty to be excited about regarding Trump 2.0 markets.
Winnebago Industries, Inc. (NYSE:WGO) shares are trading lower in the premarket session on Friday. The company reported first-quarter adjusted loss per share of 3 cents, missing the analyst consensus estimate for EPS of 20 cents. Quarterly sales were $625.60 million (down 18%), which was missing the analyst consensus estimate of $672.232 million. Revenues fell amid lower unit volume and a reduced average selling price per unit related to product mix. Gross profit was $76.8 million, a decrease of
On Thursday, the FDA granted full approval to Humacyte, Inc.’s (NASDAQ:HUMA) Symvess (acellular tissue-engineered vessel-tyod) use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss and when autologous vein graft is not feasible. Symvess, or the ATEV, is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for arterial replacement and repair. Also Read: Delay Hits Humac
On Friday, China’s central bank, the People’s Bank of China (PBOC), decided to maintain its main benchmark lending rates amid efforts to support economic growth while managing a weakening yuan. The one-year loan prime rate (LPR) remains at 3.1%, while the five-year LPR is steady at 3.6%, influencing corporate loans, household lending, and mortgages. This decision aligned with expectations from a Reuters poll of 27 economists, CNBC reports. Also Read: Amazon’s Project Kuiper In Talks With Taiwan